The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC).
Thomas Cheung Yau
No relevant relationships to disclose
Wattana Sukeepaisarnjaroen
No relevant relationships to disclose
Yee Chao
No relevant relationships to disclose
Chia-Jui Yen
No relevant relationships to disclose
Wirote Lausoontornsiri
No relevant relationships to disclose
Pei-Jer Chen
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Other Remuneration - Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; GlaxoSmithKline; GlaxoSmithKline; Roche
Theeranun Sanpajit
No relevant relationships to disclose
Riccardo Lencioni
Consultant or Advisory Role - GlaxoSmithKline
Aaron C Camp
Consultant or Advisory Role - GlaxoSmithKline
Donna S Cox
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Howard Kallender
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Lone Harild Ottesen
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Ronnie Tung-Ping Poon
No relevant relationships to disclose